Spotify
Google Podcasts
Apple Podcasts
Breaker
Overcast
Pocket Casts
Radio Public
Anchor
Akebia Therapeutics Stock Price (Quote) NASDAQ:AKBA
$2.03 ( -1.93% ) Tuesday, 25th Jan 2022
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $1.85 | $2.51 | Tuesday, 25th Jan 2022 AKBA stock ended at $2.03. This is 1.93% less than the trading day before Monday, 24th Jan 2022. During the day the stock fluctuated 6.70% from a day low at $1.94 to a day high of $2.07. |
| 90 days | $1.85 | $3.35 | |
| 52 weeks | $1.85 | $5.14 |
Historical Akebia Therapeutics prices
| Date | Open | High | Low | Close | Volume |
| 2022-01-25 | $1.95 | $2.07 | $1.94 | $2.03 | 3 255 224 |
| 2022-01-24 | $1.93 | $2.07 | $1.85 | $2.07 | 5 057 071 |
| 2022-01-21 | $2.02 | $2.09 | $1.99 | $2.00 | 3 461 936 |
| 2022-01-20 | $2.09 | $2.20 | $2.04 | $2.04 | 2 514 065 |
| 2022-01-19 | $2.09 | $2.21 | $2.08 | $2.09 | 2 786 766 |
| 2022-01-18 | $2.20 | $2.20 | $2.05 | $2.05 | 3 029 343 |
| 2022-01-14 | $2.12 | $2.21 | $2.04 | $2.20 | 4 374 149 |
| 2022-01-13 | $2.23 | $2.31 | $2.13 | $2.13 | 3 468 899 |
| 2022-01-12 | $2.29 | $2.33 | $2.20 | $2.21 | 2 764 784 |
| 2022-01-11 | $2.28 | $2.37 | $2.25 | $2.29 | 1 956 047 |
| 2022-01-10 | $2.19 | $2.28 | $2.16 | $2.27 | 2 339 183 |
| 2022-01-07 | $2.28 | $2.32 | $2.19 | $2.21 | 2 400 995 |
| 2022-01-06 | $2.26 | $2.32 | $2.20 | $2.26 | 2 746 300 |
| 2022-01-05 | $2.36 | $2.43 | $2.24 | $2.24 | 2 804 169 |
| 2022-01-04 | $2.47 | $2.49 | $2.31 | $2.36 | 2 324 174 |
| 2022-01-03 | $2.28 | $2.48 | $2.28 | $2.45 | 2 476 870 |
| 2021-12-31 | $2.29 | $2.35 | $2.24 | $2.26 | 3 532 806 |
| 2021-12-30 | $2.31 | $2.40 | $2.26 | $2.29 | 2 181 736 |
| 2021-12-29 | $2.29 | $2.33 | $2.22 | $2.29 | 2 286 894 |
| 2021-12-28 | $2.42 | $2.47 | $2.20 | $2.28 | 6 216 505 |
| 2021-12-27 | $2.50 | $2.51 | $2.39 | $2.40 | 2 479 978 |
| 2021-12-23 | $2.51 | $2.57 | $2.47 | $2.53 | 1 629 985 |
| 2021-12-22 | $2.50 | $2.53 | $2.43 | $2.48 | 2 088 721 |
| 2021-12-21 | $2.48 | $2.54 | $2.44 | $2.49 | 3 046 283 |
| 2021-12-20 | $2.39 | $2.52 | $2.35 | $2.48 | 2 794 192 |
| 2021-12-17 | $2.36 | $2.57 | $2.34 | $2.45 | 16 356 786 |
| 2021-12-16 | $2.49 | $2.49 | $2.33 | $2.37 | 3 593 853 |
| 2021-12-15 | $2.42 | $2.45 | $2.22 | $2.45 | 5 898 920 |
| 2021-12-14 | $2.50 | $2.53 | $2.36 | $2.38 | 5 024 426 |
| 2021-12-13 | $2.49 | $2.58 | $2.43 | $2.55 | 3 521 053 |
| 2021-12-10 | $2.59 | $2.63 | $2.48 | $2.50 | 2 447 439 |
| 2021-12-09 | $2.66 | $2.72 | $2.55 | $2.55 | 2 327 414 |
| 2021-12-08 | $2.72 | $2.73 | $2.63 | $2.70 | 2 132 309 |
| 2021-12-07 | $2.61 | $2.75 | $2.61 | $2.71 | 3 264 355 |
| 2021-12-06 | $2.52 | $2.59 | $2.43 | $2.54 | 2 660 714 |
| 2021-12-03 | $2.70 | $2.70 | $2.51 | $2.52 | 3 484 573 |
| 2021-12-02 | $2.56 | $2.69 | $2.52 | $2.67 | 3 256 349 |
| 2021-12-01 | $2.71 | $2.72 | $2.56 | $2.57 | 3 305 004 |
| 2021-11-30 | $2.60 | $2.74 | $2.57 | $2.71 | 3 766 414 |
| 2021-11-29 | $2.67 | $2.74 | $2.61 | $2.62 | 2 565 780 |
| 2021-11-26 | $2.75 | $2.77 | $2.63 | $2.67 | 2 404 687 |
| 2021-11-24 | $2.73 | $2.82 | $2.68 | $2.79 | 2 172 172 |
| 2021-11-23 | $2.67 | $2.78 | $2.61 | $2.75 | 2 882 825 |
| 2021-11-22 | $2.78 | $2.78 | $2.65 | $2.66 | 2 602 305 |
| 2021-11-19 | $2.76 | $2.81 | $2.72 | $2.78 | 1 783 111 |
| 2021-11-18 | $2.82 | $2.84 | $2.70 | $2.76 | 2 641 892 |
| 2021-11-17 | $2.85 | $2.90 | $2.76 | $2.80 | 2 627 361 |
| 2021-11-16 | $2.85 | $2.88 | $2.80 | $2.84 | 2 484 202 |
| 2021-11-15 | $2.89 | $2.92 | $2.84 | $2.87 | 2 592 296 |
| 2021-11-12 | $2.99 | $2.99 | $2.85 | $2.87 | 1 916 628 |
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is vadadustat, an oral therapy which has completed a Phase II study for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients; and clinical product candidate is ... Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.
This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Join 108 000+ Happy Subscribers
Don't miss out on the runners!
![StockInvest.us]()
Stock Podcast
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
